Huang C.,e Moytt Cancer Center |
Huang C.,Tianjin Medical University |
Ramakrishnan R.,e Moytt Cancer Center |
Trkulja M.,e Moytt Cancer Center |
And 2 more authors.
Cancer Immunology, Immunotherapy | Year: 2012
In this study, we tested the eVect of intratumoral administration of dendritic cells (DCs) with inducible expression of diVerent cytokines, using the novel Rheoswitch Therapeutic System on the experimental models of renal cell cancer (RENCA) and MethA sarcoma. Intratumoral injection of DCs, engineered to express IL-12, IL-21, or IFN-α, showed potent therapeutic eVect against established tumor. This eVect was associated with the induction of potent tumor antigen-specific CD8 + T-cell responses, as well as the infiltration of tumors with CD4 +and CD8 + T cells but not with the cytotoxic activity of DCs. Combination of i.t. administration of DCs, producing diVerent cytokines, did not enhance the antitumor eVect of therapy with single cytokine. These results indicate that RTS can be a potent tool for conditional topical cytokine delivery, in combination with DC administration. However, combination of diVerent cytokines may not necessarily improve the outcome of treatment. © Springer-Verlag 2012. Source